We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA has announced approval of ...

Demonstrated to significantly reduce stroke compared to warfarin, Pradaxa is first new oral anticoagulant approved by the FDA in more than 50 years RIDGEFIELD, Conn., Oct. 19 /PRNewswire/ -- The U.S.

RIDGEFIELD, Conn., March 19, 2017 /PRNewswire/ -- Important new data from the RE-CIRCUIT® study show a better safety profile for Pradaxa® (dabigatran etexilate mesylate) compared to warfarin in atrial ...

SAN FRANCISCO, CA—At ACC.13, the American College of Cardiology’s 62 nd Annual Scientific Session, leading cardiologists presented that the use of dabigatran following ablation for atrial fibrillation ...

(HealthDay News) — In clinical practice, patients starting dabigatran therapy do not have significantly different rates of ischemic stroke or extracranial hemorrhage than those starting warfarin ...

“The results we have seen from RE-DUAL PCI™ are another great piece of evidence on the benefit Pradaxa ® can offer patients with atrial fibrillation and their treating physicians; a benefit which has ...

This article is more than 10 years old. Since its approval in the United States in October 2010 dabigatran (Pradaxa) has been prescribed 3.2 million times to more than 600,000 patients with ...

The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial compared the efficacy and safety of dabigatran (Pradax in Canada and Pradaxa in Europe), a new oral direct thrombin ...

Blockbuster blood-thinner Pradaxa will come under scrutiny again, it appears. The FDA announced last Friday that it has established a study to evaluate post-trial safety outcomes in blood-thinning ...

Uninterrupted treatment with dabigatran, a non-vitamin K antagonist oral anticoagulant (NOACs), before, during and after ablation to treat atrial fibrillation significantly reduced the incidence of ...

INGELHEIM, Germany-- (BUSINESS WIRE)--Important new data from the RE-CIRCUIT ® study show a better safety profile for Pradaxa ® (dabigatran etexilate) compared to warfarin in atrial fibrillation (AF) ...